|
US9474779B2
(en)
|
2012-01-19 |
2016-10-25 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compositions and their methods of use
|
|
WO2015010297A1
(en)
|
2013-07-25 |
2015-01-29 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
NZ723859A
(en)
|
2014-03-14 |
2023-01-27 |
Servier Lab |
Pharmaceutical compositions of therapeutically active compounds and their uses
|
|
AU2015317327B9
(en)
|
2014-09-19 |
2020-04-09 |
Forma Therapeutics, Inc. |
Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
|
|
MX372964B
(es)
|
2014-09-19 |
2020-03-27 |
Forma Therapeutics Inc |
Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
|
|
MA53352A
(fr)
|
2014-09-19 |
2021-09-15 |
Forma Therapeutics Inc |
Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
|
|
EP3194383B1
(en)
|
2014-09-19 |
2019-11-06 |
Forma Therapeutics, Inc. |
Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
|
|
JP2017529382A
(ja)
|
2014-09-29 |
2017-10-05 |
アギオス ファーマシューティカルス，インコーポレーテッド |
治療活性を有する化合物及びその使用方法
|
|
JP7220986B6
(ja)
|
2015-02-04 |
2024-02-08 |
アジオス ファーマシューティカルズ， インコーポレイテッド |
治療効果のある化合物及びその使用方法
|
|
US10407419B2
(en)
|
2015-04-21 |
2019-09-10 |
Forma Therapeutics, Inc. |
Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
|
|
US9624175B2
(en)
|
2015-04-21 |
2017-04-18 |
Forma Therapeutics, Inc. |
Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
|
|
KR20180063125A
(ko)
|
2015-10-15 |
2018-06-11 |
아지오스 파마슈티컬스 아이엔씨. |
악성종양을 치료하기 위한 복합 요법
|
|
FI3362065T3
(fi)
|
2015-10-15 |
2024-06-19 |
Servier Lab |
Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi
|
|
US10695352B2
(en)
|
2015-10-15 |
2020-06-30 |
Celgene Corporation |
Combination therapy for treating malignancies
|
|
KR102699521B1
(ko)
|
2015-10-15 |
2024-08-26 |
르 라보레또레 쎄르비에르 |
악성 종양의 치료를 위한 조합물 요법
|
|
WO2017087885A1
(en)
|
2015-11-19 |
2017-05-26 |
Dana-Farber Cancer Institute, Inc. |
Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
|
|
EP3493809B1
(en)
*
|
2016-08-03 |
2023-08-23 |
Celgene Corporation |
Enasidenib for treatment of myelodysplastic syndrome
|
|
MX392941B
(es)
|
2016-09-07 |
2025-03-24 |
Celgene Corp |
Composiciones para comprimidos.
|
|
WO2018204787A1
(en)
*
|
2017-05-05 |
2018-11-08 |
Memorial Sloan Kettering Cancer Center |
Methods of treatment of myeloproliferative neoplasm
|
|
WO2019084434A1
(en)
|
2017-10-26 |
2019-05-02 |
National University Of Singapore |
NEW APPROACH FOR UNIVERSAL MONITORING OF MINIMUM RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA
|
|
WO2019109095A1
(en)
*
|
2017-12-01 |
2019-06-06 |
Beth Israel Deaconess Medical Center, Inc. |
Arsenic trioxide and retinoic acid compounds for treatment of idh2-associated disorders
|
|
US11497752B2
(en)
|
2018-01-30 |
2022-11-15 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
CN118416236A
(zh)
|
2018-01-31 |
2024-08-02 |
德西费拉制药有限责任公司 |
治疗胃肠道间质瘤的组合疗法
|
|
IL276398B2
(en)
|
2018-01-31 |
2026-03-01 |
Deciphera Pharmaceuticals Llc |
Combination therapy for mastocytosis
|
|
US11311527B2
(en)
|
2018-05-16 |
2022-04-26 |
Forma Therapeutics, Inc. |
Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
|
|
US11013734B2
(en)
|
2018-05-16 |
2021-05-25 |
Forma Therapeutics, Inc. |
Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
|
|
US11013733B2
(en)
|
2018-05-16 |
2021-05-25 |
Forma Therapeutics, Inc. |
Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
|
|
US20210196701A1
(en)
|
2018-05-16 |
2021-07-01 |
Forma Therapeutics, Inc. |
Inhibiting mutant idh-1
|
|
WO2019222551A1
(en)
|
2018-05-16 |
2019-11-21 |
Forma Therapeutics, Inc. |
Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
|
|
US10980788B2
(en)
|
2018-06-08 |
2021-04-20 |
Agios Pharmaceuticals, Inc. |
Therapy for treating malignancies
|
|
EA202190217A1
(ru)
*
|
2018-07-06 |
2021-04-16 |
Аджиос Фармасьютикалз, Инк. |
Формы ивосидениба и фармацевтические композиции
|
|
US20210299233A1
(en)
*
|
2018-07-12 |
2021-09-30 |
The Children's Medical Center Corporation |
Method for treating cancer
|
|
EP3875090A4
(en)
*
|
2018-10-31 |
2021-12-22 |
FUJIFILM Corporation |
PELLET CONTAINING AN ANTITUMOR AGENT
|
|
US20220017490A1
(en)
|
2018-11-02 |
2022-01-20 |
Celgene Corporation |
Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
|
|
WO2020092894A1
(en)
|
2018-11-02 |
2020-05-07 |
Celgene Corporation |
Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
|
|
US20220017489A1
(en)
*
|
2018-11-02 |
2022-01-20 |
Celgene Corporation |
Solid dispersions for treatment of cancer
|
|
WO2020117867A1
(en)
*
|
2018-12-03 |
2020-06-11 |
Beth Israel-Deaconess Medical Center, Inc. |
Darinaparsin and retinoic acid compounds for treatment of idh-associated disorders
|
|
WO2020117868A1
(en)
*
|
2018-12-03 |
2020-06-11 |
Beth Israel-Deaconess Medical Center, Inc. |
Arsenic compounds and retinoic acid compounds for treatment of idh-associated disorders
|
|
US12509453B2
(en)
|
2019-01-29 |
2025-12-30 |
Foghorn Therapeutics Inc. |
BRM/BRG1 inhibitors and uses thereof
|
|
WO2020185812A1
(en)
|
2019-03-11 |
2020-09-17 |
Teva Pharmaceuticals International Gmbh |
Solid state forms of ripretinib
|
|
KR102035479B1
(ko)
|
2019-04-12 |
2019-10-23 |
한국지질자원연구원 |
점토광물 복합체를 포함하는 방출성이 제어된 경구투여용 조성물
|
|
EP4013412B1
(en)
|
2019-08-12 |
2026-01-28 |
Deciphera Pharmaceuticals, LLC |
Ripretinib for treating gastrointestinal stromal tumors
|
|
TWI878335B
(zh)
|
2019-08-12 |
2025-04-01 |
美商迪賽孚爾製藥有限公司 |
治療胃腸道基質瘤方法
|
|
US12168005B2
(en)
|
2019-10-07 |
2024-12-17 |
University Hospitals Cleveland Medical Center |
Methods for treating wild type isocitrate dehydrogenase 1 cancers
|
|
CN112773797A
(zh)
*
|
2019-11-11 |
2021-05-11 |
江苏恒瑞医药股份有限公司 |
一种吡咯并六元杂环化合物在制备治疗flt3突变的肿瘤的药物中的用途
|
|
JP2023503842A
(ja)
*
|
2019-11-14 |
2023-02-01 |
セルジーン コーポレーション |
がんを処置するための小児用製剤
|
|
US12441707B2
(en)
|
2019-12-30 |
2025-10-14 |
Tyra Biosciences, Inc. |
Indazole compounds
|
|
EP4084779B1
(en)
|
2019-12-30 |
2024-10-09 |
Deciphera Pharmaceuticals, LLC |
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
|
|
MX2022008103A
(es)
|
2019-12-30 |
2022-09-19 |
Deciphera Pharmaceuticals Llc |
Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
|
|
AU2021213811A1
(en)
|
2020-01-29 |
2022-07-28 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
US12014835B2
(en)
|
2020-02-19 |
2024-06-18 |
Vanderbilt University |
Methods for evaluating therapeutic benefit of combination therapies
|
|
AU2021242260B2
(en)
*
|
2020-03-23 |
2023-12-14 |
Eli Lilly And Company |
Combination therapy with a mutant IDH inhibitor
|
|
US12383555B2
(en)
|
2020-05-20 |
2025-08-12 |
Foghorn Therapeutics Inc. |
Methods of treating cancers
|
|
TW202227138A
(zh)
*
|
2020-09-14 |
2022-07-16 |
美商托特斯藥品公司 |
治療性共軛體
|
|
CN112353800B
(zh)
*
|
2020-11-10 |
2022-06-24 |
华熙生物科技股份有限公司 |
透明质酸或其盐和/或海藻糖的组合物及其在稳定麦角硫因中的用途
|
|
US12606553B2
(en)
|
2021-03-09 |
2026-04-21 |
Foghorn Therapeutics Inc. |
Crystalline forms, compositions containing same, and methods of their use
|
|
MX2024008057A
(es)
|
2021-12-30 |
2024-08-28 |
Biomea Fusion Inc |
Compuestos de pirazina como inhibidores de flt3.
|
|
US11779572B1
(en)
|
2022-09-02 |
2023-10-10 |
Deciphera Pharmaceuticals, Llc |
Methods of treating gastrointestinal stromal tumors
|
|
WO2024249769A2
(en)
*
|
2023-06-02 |
2024-12-05 |
Foghorn Therapeutics Inc. |
Combination therapy for treating hematological cancers
|
|
CN117838863B
(zh)
*
|
2023-12-26 |
2025-03-11 |
厦门大学 |
一种抑制d2hgdh的核酸分子、抑制剂及其用途
|